Laigo Bio
Oncode Institute and Argobio launch Laigo Bio, a targeted membrane protein degradation biotech in oncology and neurological disorders
- Scientific founder : Prof. Madelon Maurice, researcher and group leader at UMC Utrecht
- The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases
- Argobio and the Oncode Institute will support the company's development to Series A financing
- Additionally secured funding from Oncode Bridge Fund
- Laigo Bio is gearing up for preclinical lead development in the coming months
- Collaborative ecosystem